CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
申请人:Novartis AG
公开号:US20220024981A1
公开(公告)日:2022-01-27
The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R
1
, X
1
, X
2
, X
3
, X
4
, X
5
, X
6
, X
7
, X
8
, X
9
, X
10
, X
11
, X
12
, and X
13
are described herein.